Salix Pharmaceuticals (SLXP) 159.83 $SLXP
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
Salix' s Xifaxan 550 sNDA Under Review, Response by Feb 28 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Sep 19, 5:10PM CDT
Salix (SLXP) is looking to expand the use of Xifaxan 550 for the treatment of irritable bowel syndrome with diarrhea.
Salix acquires additional intellectual property for rifaximin for reduction in risk of overt hepatic encephalopathy recurrence
M2 - Fri Sep 19, 6:16AM CDT
Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Thursday the receipt of exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family from Cipla.
Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN(R) 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea
Business Wire - Thu Sep 18, 12:42PM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) considers the Company's August 29, 2014 resubmission of its supplemental New Drug Application (sNDA) for XIFAXAN(R)550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D to be complete. The resubmission is considered a class 2 response to the FDA's March 7, 2011 action letter and has been assigned a user fee goal date of February 28, 2015.
Salix Secures Additional Intellectual Property Relating to Rifaximin
Business Wire - Thu Sep 18, 6:30AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Cipla Limited has granted Salix exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. Additionally, Salix and Cipla have expanded the scope of their 2009 exclusive license agreement whereby Cipla granted Salix exclusive rights in the United States, Canada and Mexico under certain patent rights covering amorphous rifaximin. By means of this amendment to the 2009 agreement, the rights already licensed to Salix in the United States, Canada and Mexico are expanded to include certain patent rights in the European Union, Japan, Australia, New Zealand and South Korea. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the "Rifaximin Complexes" patent rights. Salix also will pay royalties on net sales of products covered by the "Rifaximin Complexes" patents licensed to Salix.
AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:45PM CDT
AstraZeneca (AZN) announced that the FDA has cleared Movantik for use in adults with chronic non-cancer pain suffering from opioid-induced constipation.
3 Stocks Pushing The Health Care Sector Higher
at The Street - Wed Sep 17, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Today's Momo Momentum Stock To Watch: Salix Pharmaceuticals (SLXP)
at The Street - Wed Sep 17, 8:51AM CDT
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a momo momentum candidate
Why Salix Pharmaceuticals (SLXP) Stock Is Higher Today
at The Street - Wed Sep 17, 7:28AM CDT
Some of the top 20 investors are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals, and are pressing Salix to consider selling itself.
Salix Pharmaceuticals Rises 4.81% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Sep 16, 4:04PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $148.22 to a high of $156.29. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $149.44 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Erase Modest Gains; Netflix Gaps Below 50-Day Line
at Investor's Business Daily - Tue Sep 16, 11:12AM CDT
Stocks held on to modest gains about two hours into Tuesday's session, one day after the Nasdaq notched its third distribution day in five trading sessions. The S&P 500 gained 0.4%; the Dow Jones industrial average added 0.2% and the Nasdaq rose...
Video: Valeant, Allergan Settle Suit, Allow Shareholder Vote
at Investor's Business Daily - Tue Sep 16, 10:36AM CDT
Specialty-drug giant Valeant Pharmaceuticals International (VRX) agreed to drop its litigation against hostile-takeover target Allergan in exchange for Allergan allowing the originally scheduled Dec. 18 special shareholder meeting that could speed...
UCERIS(R) (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA
Business Wire - Mon Sep 15, 4:31PM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the FDA has granted tentative approval for UCERIS(R) (budesonide) rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC) extending up to 40cm from the anal verge. The foam is a rectally administered corticosteroid that overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon.
Nasdaq Sinks As Tesla, Other Highfliers Get Hit
at Investor's Business Daily - Mon Sep 15, 3:31PM CDT
Major averages ended mixed Monday but the Nasdaq continued to sell off into the close. The Nasdaq slumped 1.1%, while the S&P 500 fell less than 0.1% and the Dow bucked the downdraft with a 0.3% gain. Volume ran higher on the Nasdaq but lower on the...
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire
PR Newswire - Mon Sep 15, 7:50AM CDT
Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Covidien plc (NYSE: COV) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6458-100free.
Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...
Stocks Drag Lower Despite Data; Conversant Soars On ADS Buyout
at Investor's Business Daily - Fri Sep 12, 9:37AM CDT
Stocks leaned lower out of the starting gate Friday, despite an early raft of strong economic data. The Nasdaq and the S&P 500 each dimmed 0.4%. The Dow Jones industrial average backed down 0.3%. Volume was mild to lower, up 1% on the NYSE and down...
Salix Pharmaceuticals Shares Up 35.6% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Wed Sep 10, 4:44PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 5 months, Salix Pharmaceuticals has returned 35.64% as of today's recent price of $147.94.
After Yesterday's Decline of 3.16%, Salix Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Sep 10, 4:02PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $147.56 to a high of $153.26. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $151.32 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
IBD 50 Stocks Setting Up, Including These 5 Medicals
at Investor's Business Daily - Fri Sep 19, 6:36PM CDT
Recent volatility in the stock market, including an outlook shift to uptrend under pressure and back to a confirmed uptrend, may have rattled investors' nerves. But it's also helped set up new potential entries as some leading stocks slipped into buy...
Salix' s Xifaxan 550 sNDA Under Review, Response by Feb 28 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Sep 19, 5:10PM CDT
Salix (SLXP) is looking to expand the use of Xifaxan 550 for the treatment of irritable bowel syndrome with diarrhea.
Salix acquires additional intellectual property for rifaximin for reduction in risk of overt hepatic encephalopathy recurrence
M2 - Fri Sep 19, 6:16AM CDT
Salix Pharmaceuticals (NasdaqGS:SLXP) reported on Thursday the receipt of exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family from Cipla.
Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN(R) 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea
Business Wire - Thu Sep 18, 12:42PM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) considers the Company's August 29, 2014 resubmission of its supplemental New Drug Application (sNDA) for XIFAXAN(R)550 mg tablets for the proposed indication of the treatment of irritable bowel syndrome with diarrhea or IBS-D to be complete. The resubmission is considered a class 2 response to the FDA's March 7, 2011 action letter and has been assigned a user fee goal date of February 28, 2015.
Salix Secures Additional Intellectual Property Relating to Rifaximin
Business Wire - Thu Sep 18, 6:30AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Cipla Limited has granted Salix exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. Additionally, Salix and Cipla have expanded the scope of their 2009 exclusive license agreement whereby Cipla granted Salix exclusive rights in the United States, Canada and Mexico under certain patent rights covering amorphous rifaximin. By means of this amendment to the 2009 agreement, the rights already licensed to Salix in the United States, Canada and Mexico are expanded to include certain patent rights in the European Union, Japan, Australia, New Zealand and South Korea. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the "Rifaximin Complexes" patent rights. Salix also will pay royalties on net sales of products covered by the "Rifaximin Complexes" patents licensed to Salix.
AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:45PM CDT
AstraZeneca (AZN) announced that the FDA has cleared Movantik for use in adults with chronic non-cancer pain suffering from opioid-induced constipation.
3 Stocks Pushing The Health Care Sector Higher
at The Street - Wed Sep 17, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Today's Momo Momentum Stock To Watch: Salix Pharmaceuticals (SLXP)
at The Street - Wed Sep 17, 8:51AM CDT
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a momo momentum candidate
Why Salix Pharmaceuticals (SLXP) Stock Is Higher Today
at The Street - Wed Sep 17, 7:28AM CDT
Some of the top 20 investors are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals, and are pressing Salix to consider selling itself.
Salix Pharmaceuticals Rises 4.81% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Sep 16, 4:04PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $148.22 to a high of $156.29. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $149.44 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Erase Modest Gains; Netflix Gaps Below 50-Day Line
at Investor's Business Daily - Tue Sep 16, 11:12AM CDT
Stocks held on to modest gains about two hours into Tuesday's session, one day after the Nasdaq notched its third distribution day in five trading sessions. The S&P 500 gained 0.4%; the Dow Jones industrial average added 0.2% and the Nasdaq rose...
Video: Valeant, Allergan Settle Suit, Allow Shareholder Vote
at Investor's Business Daily - Tue Sep 16, 10:36AM CDT
Specialty-drug giant Valeant Pharmaceuticals International (VRX) agreed to drop its litigation against hostile-takeover target Allergan in exchange for Allergan allowing the originally scheduled Dec. 18 special shareholder meeting that could speed...
UCERIS(R) (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA
Business Wire - Mon Sep 15, 4:31PM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the FDA has granted tentative approval for UCERIS(R) (budesonide) rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC) extending up to 40cm from the anal verge. The foam is a rectally administered corticosteroid that overcomes treatment limitations associated with currently approved therapies which are often ineffective due to insufficient distribution of active drug to the distal colon.
Nasdaq Sinks As Tesla, Other Highfliers Get Hit
at Investor's Business Daily - Mon Sep 15, 3:31PM CDT
Major averages ended mixed Monday but the Nasdaq continued to sell off into the close. The Nasdaq slumped 1.1%, while the S&P 500 fell less than 0.1% and the Dow bucked the downdraft with a 0.3% gain. Volume ran higher on the Nasdaq but lower on the...
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire
PR Newswire - Mon Sep 15, 7:50AM CDT
Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Covidien plc (NYSE: COV) and Shire plc (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6458-100free.
Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers
at Investor's Business Daily - Sat Sep 13, 7:02AM CDT
Biotech and pharmaceutical companies are on the rise with life-saving promises, adding to hopes that their stocks will also be healthy investments. The industry was down Friday on general market weakness and concerns over growth stocks. But it...
Stocks Drag Lower Despite Data; Conversant Soars On ADS Buyout
at Investor's Business Daily - Fri Sep 12, 9:37AM CDT
Stocks leaned lower out of the starting gate Friday, despite an early raft of strong economic data. The Nasdaq and the S&P 500 each dimmed 0.4%. The Dow Jones industrial average backed down 0.3%. Volume was mild to lower, up 1% on the NYSE and down...
Salix Pharmaceuticals Shares Up 35.6% Since SmarTrend's Buy Recommendation (SLXP)
Comtex SmarTrend(R) - Wed Sep 10, 4:44PM CDT
SmarTrend identified an Uptrend for Salix Pharmaceuticals (NASDAQ:SLXP) on April 22nd, 2014 at $109.07. In approximately 5 months, Salix Pharmaceuticals has returned 35.64% as of today's recent price of $147.94.
After Yesterday's Decline of 3.16%, Salix Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Wed Sep 10, 4:02PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $147.56 to a high of $153.26. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $151.32 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
